Neurosense Therapeutics Ltd. NRSN 深 滬
等待開盤 09-26 09:30:00 美东时间
1.1979
-0.042
-3.40%
華盛通- 最 高1.24
- 今 開1.22
- 成交量 18.74万股
- 最 低 1.15
- 昨 收 1.24
- 總市值 2999.94万
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 0.75%
- 52周最低 0.80
- 委 比 70.01%
- 總股本 2504.33万
- 歷史最高 8.18
- 量 比 2.14
- 振 幅 7.26%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an announcement. On Septemb...
09-11 02:59
NeuroSense Reports Phase 2 RoAD Trial Results, Says PrimeC Boosts Brain Connectivity In Alzheimer's, Shows Favorable Safety Profile
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profileCAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics
09-11 02:32
NeuroSense Therapeutics announces $500,000 private placement
NeuroSense Therapeutics (NASDAQ:NRSN) announced on Thursday it has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares. Under the terms of t...
09-04 21:16
NeuroSense Announces $500,000 Private Placement Of 333,334 Shares At $1.50/Share
Financing at 40% premium to market price provides near-term bridge to anticipated milestonesCAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical
09-04 20:50
NeuroSense Reports Statistically Significant 18-Month Phase 2b Data Showing PrimeC Slows ALS Progression With Early Treatment Advantage
NeuroSense Therapeutics Ltd. today announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS. ●Statistically significant effect at 18 months (p=0.03) demonstrated by NfL-adjusted
09-02 20:42
NeuroSense Reports Long-Term Safety of PrimeC in ALS Study
The latest update is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). As of A...
08-20 21:57
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
08-15 19:15
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
07-10 20:25
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
05-13 08:50
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch
Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an announcement. On May ...
05-07 21:29
